Tazomeline

Tazomeline
Clinical data
ATC code
  • None
Identifiers
IUPAC name
  • 5-[4-(hexylsulfanyl)-1,2,5-thiadiazol-3-yl]-1-methyl-1,2,3,6-tetrahydropyridine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H23N3S2
Molar mass297.48 g·mol−1
3D model (JSmol)
SMILES
  • n2snc(/C1=C/CCN(C)C1)c2SCCCCCC

Tazomeline (LY-287,041) is a drug which acts as a non-selective muscarinic acetylcholine receptor agonist.[1][2] It was in clinical trials for the treatment of cognitive dysfunction such as that seen in Alzheimer's disease and schizophrenia, but development was apparently scrapped for unknown reasons.[1][2][3]

See also

References

  1. 1 2 Langmead CJ, Watson J, Reavill C (February 2008). "Muscarinic acetylcholine receptors as CNS drug targets". Pharmacology & Therapeutics. 117 (2): 232–43. doi:10.1016/j.pharmthera.2007.09.009. PMID 18082893.
  2. 1 2 Amos D Korczyn (October 2000). "Muscarinic M1 Agonists in the Treatment of Alzheimer's Disease". Expert Opinion on Investigational Drugs. 9 (10): 2259–2267(9). doi:10.1517/13543784.9.10.2259. PMID 11060805. S2CID 32214700.
  3. ↑ Mashkovskii MD, Glushkov RG (April 2001). "Drugs for the Treatment of Alzheimer's Disease". Pharmaceutical Chemistry Journal. 35 (4): 179–182. doi:10.1023/A:1010474325601. S2CID 39866378.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.